Compared with vehicle-treated group, BP-Combo significantly reduced the incidences of both myr-AKT/NRasG12V- (vehicle vs. BP-combo: 9/9 vs. 1/7) and c-Myc/sgTP53-induced liver tumors (vehicle vs. BP-combo: 6/7 vs. 4/10), and also decreased the number and size of tumor nodules (Fig. 7a–c), suggesting an inhibitory role of BP-Combo on liver cancer formation and growth. Here, AKT1 is linked to liver cancer.